Stockscreener 앱 받기
196.19
1.57%
3.16
전일 마감가:
$193.03
열려 있는:
$197.08
하루 거래량:
171.75K
Relative Volume:
0.17
시가총액:
$9.66B
수익:
$4.06B
순이익/손실:
$413.08M
주가수익비율:
24.49
EPS:
8.01
순현금흐름:
$560.48M
1주 성능:
+4.78%
1개월 성능:
+16.83%
6개월 성능:
+31.18%
1년 성능:
+2.94%
1일 변동 폭
$195.10
$200.58
1주일 범위
$185.93
$200.58
52주 변동 폭
$91.86
$200.58
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
CRL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
196.20 | 9.50B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
567.24 | 215.01B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
226.11 | 159.87B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
704.37 | 56.23B | 4.17B | 1.03B | 940.22M | 12.61 |
|
A
Agilent Technologies Inc
|
140.68 | 39.54B | 6.95B | 1.30B | 1.15B | 4.5714 |
|
IQV
Iqvia Holdings Inc
|
222.37 | 37.85B | 15.90B | 1.28B | 2.21B | 7.2842 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-17 | 업그레이드 | Argus | Hold → Buy |
| 2025-11-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Barclays Adjusts PT on Charles River Laboratories International to $215 From $210, Keeps Overweight Rating - marketscreener.com
Charles River Laboratories stock hits 52-week high at 200.51 USD - Investing.com
Charles River Laboratories International (NYSE:CRL) Upgraded at Bank of America - MarketBeat
JPMorgan Adjusts Charles River Laboratories International PT to $190 From $165, Maintains Neutral Rating - marketscreener.com
Charles River Labs stock rating upgraded by BofA on early research exposure - Investing.com
Charles River (CRL) Receives Upgrade Amid Biopharma Market Changes - GuruFocus
National Bank of Canada FI Boosts Stock Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Assessing Charles River Laboratories (CRL) Valuation as Its Cell & Gene Therapy Incubator Program Expands - simplywall.st
Charles River Laboratories International (NYSE:CRL) Stock Rating Lowered by Wall Street Zen - MarketBeat
Sei Investments Co. Buys 39,959 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Bayesian Capital Management LP Takes Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories (CRL): Reassessing Valuation After a Quiet Share Price Rebound - Sahm
Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort - PharmiWeb.com
Charles River Laboratories International, Inc. $CRL Shares Sold by Investment House LLC - MarketBeat
Pre-clinical trial giant eyes organ-on-a-chip companies after activist investor pressure - The Business Journals
Federated Hermes Inc. Raises Stock Holdings in Charles River Laboratories International, Inc. $CRL - MarketBeat
13D Management LLC Invests $4.25 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat
What's Driving the Market Sentiment Around Charles River Laboratories International Inc? - Benzinga
Ariel Investments LLC Purchases 314,572 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories International, Inc. $CRL Shares Acquired by Amundi - MarketBeat
Charles River Laboratories International, Inc. $CRL Shares Acquired by Bank of Nova Scotia - MarketBeat
Invesco Ltd. Purchases 128,785 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Burgundy Asset Management Ltd. Buys 277,450 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Russell Investments Group Ltd. Buys 11,667 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
What Charles River Laboratories International (CRL)'s Strengthening DSA Bookings Trend Means For Shareholders - Yahoo Finance
Charles River Laboratories Tops Q3 Estimates, Tightens Full-Year Outlook - MSN
Charles River Laboratories International, Inc. (NYSE:CRL) Q3 2025 Earnings Call Transcript - MSN
Edgestream Partners L.P. Invests $1.80 Million in Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Laboratories credit outlook lowered to stable at S&P on weak 2025 guidance - MSN
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MSN
Kennedy Capital Management LLC Lowers Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
Norges Bank Makes New Investment in Charles River Laboratories International, Inc. $CRL - MarketBeat
What Charles River Laboratories International (CRL)'s Improving Discovery and Safety Assessment Bookings Trend Means For Shareholders - simplywall.st
Why Charles River Laboratories International Inc. stock is recommended by analystsGold Moves & Short-Term Trading Alerts - Newser
Will Charles River Laboratories International Inc. (RV6) stock split increase liquidityJuly 2025 Levels & High Accuracy Buy Signal Tips - Newser
Why Charles River Laboratories International Inc. stock could break out in 2025Market Trend Report & Capital Efficiency Focused Strategies - Newser
Charles River Laboratories (CRL) Stock Declines Amid FDA Announcement - GuruFocus
Can Charles River Laboratories International Inc. (RV6) stock test all time highsQuarterly Market Review & Low Volatility Stock Recommendations - Newser
CROs fall as FDA head Makary says drug approvals will require fewer trials ( - Seeking Alpha
New York State Common Retirement Fund Reduces Position in Charles River Laboratories International, Inc. $CRL - MarketBeat
What analyst consensus implies for Charles River Laboratories International Inc. stock2025 Major Catalysts & High Yield Equity Trading Tips - Newser
What insider trading reveals about Charles River Laboratories International Inc. stockEarnings Summary Report & Weekly High Potential Stock Alerts - Newser
How strong is Charles River Laboratories International Inc. (RV6) stock earnings growthWeekly Market Report & Low Risk Entry Point Guides - Newser
Arrowstreet Capital Limited Partnership Purchases 225,027 Shares of Charles River Laboratories International, Inc. $CRL - MarketBeat
Charles River Labs Joins Evercore Healthcare Conference - The Globe and Mail
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MSN
Charles River Laboratories (CRL) Shares Skyrocket, What You Need To Know - Finviz
CRL Stock Rises on Improved DSA Demand & Upward Trends | Dec 2025News and Statistics - IndexBox
Transcript : Charles River Laboratories International, Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 10 - marketscreener.com
Charles River Laboratories (CRL) Updates on Fourth-Quarter Deman - GuruFocus
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
0.88%
자본화:
|
볼륨(24시간):